LIVIVO - Search results -

Search results

Result 1 - 10 of total 325

Search options

Article: Cerebellar Neurocysticercosis as Long-Term Complication of Allogeneic Haematopoietic Stem Cell Transplantation from Haploidentical Donor.

Meconi, Federico / Ciangola, Giulia / Mariotti, Benedetta / Cerretti, Raffaella / Cudillo, Laura / Arcese, William / Picardi, Alessandra

Case reports in infectious diseases

2019 Volume 2019, Page(s) 4603130

Abstract: Neurocysticercosis, an infection of the central nervous system with the larval stage of the ... ...

Abstract	Neurocysticercosis, an infection of the central nervous system with the larval stage of the cestode
Language	English
Publishing date	2019-09-19
Publishing country	Egypt
Document type	Case Reports
ZDB-ID	2627642-2
ISSN	2090-6633 ; 2090-6625
ISSN (online)	2090-6633
ISSN	2090-6625
DOI	10.1155/2019/4603130
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931- July 15, 2018.

Amadori, Sergio / Arcese, William / Avvisati, Giuseppe / Gale, Robert Peter / Lo-Coco, Francesco

Leukemia

2019 Volume 33, Issue 2, Page(s) 285–286

Language	English
Publishing date	2019-01-11
Publishing country	England
Document type	Journal Article
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-018-0352-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Battipaglia, Giorgia / Labopin, Myriam / Mielke, Stephan / Ruggeri, Annalisa / Nur Ozkurt, Zubeyde / Bourhis, Jean Henri / Rabitsch, Werner / Yakoub-Agha, Ibrahim / Grillo, Giovanni / Sanz, Jaime / Arcese, William / Novis, Yana / Fegueux, Nathalie / Spyridonidis, Alexandros / Giebel, Sebastian / Nagler, Arnon / Ciceri, Fabio / Mohty, Mohamad

Transplantation and cellular therapy

2023 Volume 30, Issue 1, Page(s) 95.e1–95.e10

Abstract: Total body irradiation (TBI) at myeloablative doses is superior to chemotherapy-based regimens in young patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, in elderly and ... ...

Abstract	Total body irradiation (TBI) at myeloablative doses is superior to chemotherapy-based regimens in young patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, in elderly and unfit patients, in whom reduced-intensity conditioning (RIC) regimens are preferred, whether a TBI-based or a chemotherapy-based approach is better is unexplored. Thiotepa can be used as part of ALL conditioning regimens. The current study aimed to compare transplantation outcomes after RIC with TBI-based or thiotepa-based regimens in patients with ALL. The study cohort comprised patients aged ≥40 years undergoing allo-HSCT for ALL in first complete remission between 2000 and 2020 who received an RIC regimen containing either TBI (4 to 6 Gy) or thiotepa. We identified a total of 265 patients, including 117 who received a TBI-based RIC regimen and 148 who received a thiotepa-based RIC regimen. Univariate analysis revealed no significant differences in the following transplantation outcomes for TBI versus thiotepa: relapse, 23% versus 28% (P = .24); nonrelapse mortality, 20% versus 26% (P = .61); leukemia-free survival, 57% versus 46% (P = .12); overall survival, 67% versus 56% (P = .18); graft-versus-host disease (GVHD]/relapse-free survival, 45% versus 38% (P = .21); grade II-IV acute GVHD, 30% in both groups (P = .84); grade III-IV acute GVHD, 9% versus 10% (P = .89). The sole exception was the incidence of chronic GVHD, which was higher in the recipients of TBI-based regimens (43% versus 29%; P = .03). However, multivariate analysis revealed no differences in transplantation outcomes between the 2 groups. In patients aged ≥40 years receiving RIC, use of a thiotepa-based regimen may represent a valid alternative to TBI-based regimens, as no differences were observed in the main transplantation outcomes.
MeSH term(s)	Aged ; Humans ; Thiotepa/therapeutic use ; Retrospective Studies ; Whole-Body Irradiation/adverse effects ; Bone Marrow ; Leukemia, Myeloid, Acute/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Acute Disease ; Graft vs Host Disease/prevention & control
Chemical Substances	Thiotepa (905Z5W3GKH)
Language	English
Publishing date	2023-10-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2023.09.028
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.

Sanz, Jaime / Labopin, Myriam / Pabst, Thomas / Versluis, Jurjen / Van Gorkom, Gwendolyn / Meijer, Ellen / Gedde-Dahl, Tobias / Montoro, Juan / Arcese, William / Pérez-Simón, Jose Antonio / Schaap, Nicolaas / Maertens, Johan / Vrhovac, Radovan / Lanza, Francesco / Gorin, Norbert Claude / Mohty, Mohamad / Ciceri, Fabio

Bone marrow transplantation

2023 Volume 58, Issue 11, Page(s) 1197–1202

Abstract: We retrospectively compared the impact of the conditioning regimen in adult patients with acute myeloid leukemia (AML) in first complete remission (CR1) that received high-dose myeloablative chemotherapy followed by autologous stem cell transplantation ( ... ...

Abstract	We retrospectively compared the impact of the conditioning regimen in adult patients with acute myeloid leukemia (AML) in first complete remission (CR1) that received high-dose myeloablative chemotherapy followed by autologous stem cell transplantation (ASCT) from 2010 to 2021 with either high-dose cytarabine, etoposide and busulfan (BEA), busulfan with cyclophosphamide (BUCY) or busulfan and high-dose melphalan (BUMEL) registered in the EBMT database. Overall 1560 patients underwent ASCT, of which 156, 1143 and 261 received BEA, BUCY and BUMEL, respectively. Compared to BUCY and BUMEL, BEA patients were younger (p < 0.001) and less frequently had NPM1 mutations (p = 0.03). Transplant outcomes at 5 years with BEA, BUCY and BUMEL were: cumulative incidence of relapse 41.8%, 46.6% and 51.6%; non-relapse mortality (NRM) 1.5%, 5.2% and 7.3%; probability of leukemia-free survival (LFS) 56.7%, 48.2% and 41.1%; and overall survival (OS) 71.3%, 62.3% and 56%, respectively. In multivariable analysis the BEA regimen showed significant improvement in OS compared to BUCY (hazard ratio [HR] 0.65; 95% CI, 0.42-0.83; p = 0.048) and BUMEL (HR 0.59; 95% CI, 0.37-0.94; p = 0.029). In conclusion, high-dose myeloablative combination chemotherapy with BEA offered improved outcomes compared to classical BUCY or BUMEL in patients with AML in CR1 undergoing ASCT.
MeSH term(s)	Humans ; Adult ; Hematopoietic Stem Cell Transplantation ; Melphalan/therapeutic use ; Busulfan ; Etoposide/therapeutic use ; Cytarabine/therapeutic use ; Retrospective Studies ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Leukemia, Myeloid, Acute/drug therapy ; Cyclophosphamide/therapeutic use ; Acute Disease ; Transplantation Conditioning
Chemical Substances	Melphalan (Q41OR9510P) ; Busulfan (G1LN9045DK) ; Etoposide (6PLQ3CP4P3) ; Cytarabine (04079A1RDZ) ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2023-08-08
Publishing country	England
Document type	Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-023-02075-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.

Cristiano, Antonio / Palmieri, Raffaele / Fabiani, Emiliano / Ottone, Tiziana / Divona, Mariadomenica / Savi, Arianna / Buccisano, Francesco / Maurillo, Luca / Tarella, Corrado / Arcese, William / Voso, Maria Teresa

Mediterranean journal of hematology and infectious diseases

2022 Volume 14, Issue 1, Page(s) e2022041

Abstract: The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves the probability of complete remission and prolongs survival in patients with Acute Myeloid Leukemia (AML) when compared to HMA alone. However, the mutated clone ... ...

Abstract	The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves the probability of complete remission and prolongs survival in patients with Acute Myeloid Leukemia (AML) when compared to HMA alone. However, the mutated clone composition may impact the probability of response and its duration. Here, we describe the molecular profile of a patient with AML rapidly evolved from a previous therapy-related-Chronic MyeloMonocytic Leukemia, who achieved safely complete remission after treatment with the VEN/Azacitidine combination, even in the presence of SARS-COVID-2 infection. The targeted NGS analysis showed that the VEN/AZA combination led to the eradication of the
Language	English
Publishing date	2022-05-01
Publishing country	Italy
Document type	Case Reports
ZDB-ID	2674750-9
ISSN	2035-3006
ISSN	2035-3006
DOI	10.4084/MJHID.2022.041
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.

Candoni, Anna / Lazzarotto, Davide / Rambaldi, Alessandro / Dubbini, Maria Vittoria / Bresciani, Paola / Busca, Alessandro / Arcese, William / Iori, Anna Paola / Sorasio, Roberto / Irrera, Giuseppe / Fanin, Renato / Ciceri, Fabio / Bonifazi, Francesca

Bone marrow transplantation

2022 Volume 57, Issue 5, Page(s) 834–836

MeSH term(s)	Fusion Proteins, bcr-abl/genetics ; Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Chemical Substances	Protein Kinase Inhibitors ; Fusion Proteins, bcr-abl (EC 2.7.10.2)
Language	English
Publishing date	2022-02-24
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-022-01618-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome.

Compagno, Mirko / Navarra, Assunta / Campogiani, Laura / Coppola, Luigi / Rossi, Benedetta / Iannetta, Marco / Malagnino, Vincenzo / Parisi, Saverio G / Mariotti, Benedetta / Cerretti, Raffaella / Arcese, William / Goletti, Delia / Andreoni, Massimo / Sarmati, Loredana

International journal of environmental research and public health

2022 Volume 19, Issue 17

Abstract: The results of tuberculosis (TB) screening and reactivation in a cohort of 323 adult patients undergoing haematopoietic stem cell transplantation (HSCT) from 2015 to 2019 at the University Hospital of Tor Vergata, Rome, Italy, were reported. A total of ... ...

Abstract	The results of tuberculosis (TB) screening and reactivation in a cohort of 323 adult patients undergoing haematopoietic stem cell transplantation (HSCT) from 2015 to 2019 at the University Hospital of Tor Vergata, Rome, Italy, were reported. A total of 260 patients, 59 (18.3%) autologous and 264 (81.7%) allogeneic transplants, underwent Interferon Release (IFN)-γ (IGRA) test screening: 228 (87.7%) were negative, 11 (4.2%) indeterminate and 21 (8.1%) positive. Most of the IGRA-positive patients were of Italian origin (95.2%) and significantly older than the IGRA-negative (
MeSH term(s)	Adult ; Cohort Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hospitals ; Humans ; Interferon-gamma Release Tests/methods ; Latent Tuberculosis/diagnosis ; Latent Tuberculosis/epidemiology ; Retrospective Studies ; Rome/epidemiology ; Tuberculin Test/methods ; Tuberculosis/diagnosis ; Tuberculosis/epidemiology
Language	English
Publishing date	2022-08-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2175195-X
ISSN	1660-4601 ; 1661-7827
ISSN (online)	1660-4601
ISSN	1661-7827
DOI	10.3390/ijerph191710693
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies.

Noguera, N I / Catalano, G / Banella, C / Divona, M / Faraoni, I / Ottone, T / Arcese, W / Voso, M T

Cancers

2019 Volume 11, Issue 10

Abstract: This review highlights new findings that have deepened our understanding of the mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia (APL). Promyelocytic leukemia-retinoic acid receptor α (PML-RARa) sets the cellular ... ...

Abstract	This review highlights new findings that have deepened our understanding of the mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia (APL). Promyelocytic leukemia-retinoic acid receptor α (PML-RARa) sets the cellular landscape of acute promyelocytic leukemia (APL) by repressing the transcription of RARa target genes and disrupting PML-NBs. The RAR receptors control the homeostasis of tissue growth, modeling and regeneration, and PML-NBs are involved in self-renewal of normal and cancer stem cells, DNA damage response, senescence and stress response. The additional somatic mutations in APL mainly involve FLT3, WT1, NRAS, KRAS, ARID1B and ARID1A genes. The treatment outcomes in patients with newly diagnosed APL improved dramatically since the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). ATRA activates the transcription of blocked genes and degrades PML-RARα, while ATO degrades PML-RARa by promoting apoptosis and has a pro-oxidant effect. The resistance to ATRA and ATO may derive from the mutations in the RARa ligand binding domain (LBD) and in the PML-B2 domain of PML-RARa, but such mutations cannot explain the majority of resistances experienced in the clinic, globally accounting for 5-10% of cases. Several studies are ongoing to unravel clonal evolution and resistance, suggesting the therapeutic potential of new retinoid molecules and combinatorial treatments of ATRA or ATO with different drugs acting through alternative mechanisms of action, which may lead to synergistic effects on growth control or the induction of apoptosis in APL cells.
Language	English
Publishing date	2019-10-18
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers11101591
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Identification of oral risk factors for chronic graft versus host disease in haematological patients who underwent allogeneic haematopoietic stem cell transplantation.

Picardi, A / Miranda, M / Liciani, F / Paterno, G / Arcese, W / Bollero, P

ORAL & implantology

2017 Volume 10, Issue 4, Page(s) 390–397

Abstract: Objective: The aim of this prospective observational study was to identify local risk factors for the development of clinical manifestations of oral chronic Graft versus Host Disease (cGvHD) in a cohort of patients affected by haematological malignant ... ...

Abstract	Objective: The aim of this prospective observational study was to identify local risk factors for the development of clinical manifestations of oral chronic Graft versus Host Disease (cGvHD) in a cohort of patients affected by haematological malignant diseases who underwent allogeneic haematopoietic stem cell transplantation (HSCT). Materials and methods: In the context of an active collaboration between the Rome Transplant Network of the Hematology and the Oral Pathology Division at "Policlinico Tor Vergata", in Rome, 47 haematological patients were included in this trial based on a systematic dental screening and follow-up protocol. The dental checks were planned 1 month before the transplant procedure while the subsequent follow ups were scheduled on day +100, +180, +365 and + 730 after the transplant. The tool used for the dental checks was a detailed report including all the potential oral features responsible of mechanical, chemical or infective injuries, except for the drugs. Results: Overall, 64% of patients (N=30) did not perform dental hygiene during the screening pre-transplant and 53% (25/47) developed cGvHD with oral involvement. The most part of patients (84%) who experienced oral manifestations of cGvHD during the follow-up period after HSCT did not perform dental hygiene before the transplant procedure. Moreover, the comparison between the "presence" or "absence" of dental hygiene before the allogeneic HSCT showed a statistical significant increasing during the follow-up period in the occurrence of oral lesions due to the cGvHD for patients who lack pre-transplant dental care (p=0.029).On the contrary, the frequency of the other factors such as malocclusions, fractured teeth, incongruous prosthesis, food, smoke, alcol and bad habits, resulted similar between the group with or without typical oral lesions of cGvHD. Conclusions: The prevention of oral infectious complications provided by primary and secondary dental cares can result in a great benefit for haematological patients who underwent allogeneic HSCT. The combined hematological and dental management represents a clinical need before and after allogeneic HSCT for the removal of inconvenient issues with impact on the short and long-term outcome. Poor dental hygiene seems to be a local risk factor for the development of oral lesions due to cGvHD. However, a larger cohort of patients is necessary to confirm these preliminary data and to evaluate the best preventive and therapeutic oral hygiene protocol in this specific setting.
Language	English
Publishing date	2017-01-21
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2700308-5
ISSN	2035-2468 ; 1974-5648
ISSN (online)	2035-2468
ISSN	1974-5648
DOI	10.11138/orl/2017.10.4.390
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin.

Meconi, Federico / Provenzano, Ida / Nasso, Daniela / Mariotti, Benedetta / Pupo, Livio / Secchi, Roberto / Cerretti, Raffaella / Lucia, Anemona / Arcese, William / Cantonetti, Maria

Clinical case reports

2020 Volume 8, Issue 8, Page(s) 1353–1356

Abstract: Occasionally, non-Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T-cell NHL with both nodal and extranodal involvement. ... ...

Abstract	Occasionally, non-Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T-cell NHL with both nodal and extranodal involvement. Brentuximab vedotin could be an effective choice in treating metachronous T-cell NHL.
Language	English
Publishing date	2020-05-05
Publishing country	England
Document type	Case Reports
ZDB-ID	2740234-4
ISSN	2050-0904
ISSN	2050-0904
DOI	10.1002/ccr3.2898
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito